drugset / Trial / NCT02487498

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT02487498

Phase 3 Completed 355 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.

Timeline

Start
2015-07-27
Primary completion
2016-09-06
Completion
2016-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 15.6 ug Inhaled
Subject Indacaterol Other / unclassified 27.5 ug Inhaled
Subject Umeclidinium Other / unclassified 62.5 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled